AbbVie Reports Strong Sales Growth for Skyrizi and Rinvoq, Boosts 2027 Revenue Outlook

The pharmaceutical giant's fourth-quarter performance exceeded expectations, offsetting sharp declines in Humira sales with surging demand for its newer immunology drugs.

• AbbVie reported fourth-quarter revenue of $15.1 billion, surpassing analyst expectations of $14.8 billion, driven by strong sales of Skyrizi and Rinvoq.
• Skyrizi sales increased by 58% year-over-year to $3.78 billion, while Rinvoq sales grew 46% to $1.83 billion, both exceeding forecasts.
• Humira sales dropped 49% to $1.68 billion due to competition from biosimilars, marking a steep decline for the former top-selling drug.
• The company raised its 2027 revenue projections for Skyrizi and Rinvoq to over $31 billion combined, up from a previous estimate of $27 billion.
• AbbVie expects high single-digit annual growth for its aesthetics business through 2029 and forecasts adjusted 2025 earnings per share of $12.12-$12.32.

4 Articles

Investopedia Investor's Business Daily Sherwood News